

OVARIAN CANCER AGE-ADJUSTED MORTALITY RATES IN CHILE DURING 2002-2019.

Authors: dos Santos, FM¹, Caputo, M¹, Romero, JF¹. Affiliations: ¹Medical Department, GSK, Santiago, Chile

Background & Aims

Ovarian cancer (OC) is a public health priority in Chile, with diagnosis and treatment been guaranteed by the Explicit Health Guarantees (GES) program since 2013 (1). Advances in treatment and changes in clinical practice may impact on OC mortality rates. Our objective was to identify the most affected age groups and Chilean regions related to mortality rate.

Methods

- Deaths: ICD-10 C56, C57.0, C48.1, C48.2 (2)
- Population projection: National Statistics Institute (3).
- Age-adjusted mortality rates (AAMR) per 100,000 habitants were estimated using the direct method applying age-specific rates in a population of interest to a standardized age distribution using the 2022 population as reference, at the national level and at the 7 most populous Chilean regions.

Four age groups were defined:

- Premenopausal (15-49)
- Postmenopausal (50-64)
- 3rd age (65-79)
- 4th age (80+) women

Evaluations were made for the entire period and by 2002-2013 (pre-GES) and 2014-2019 (post-GES) and assessed qualitative.

- The total period was evaluated and stratified into 2002-2013 (pre-GES) and 2014-2019 (post-GES) and assessed qualitative.

Conclusions




- OC mortality was higher in postmenopausal and 3rd age women.
- Nationally, the mean AAMR have decreased after GES implementation, although in certain regions there was an increase, which may have been influenced by different regional GES implementation practices.



OC mortality is higher in postmenopausal and 3rd age women, with certain Chilean regions presenting increasing mortality rates





Results



Most deaths occurred in the postmenopausal (35%) and 3rd age women (35%). AAMR are described only for these subgroups as they accounted for the majority of deaths.

Postmenopausal and 3rd age AAMR description in the 7 most populous Chilean regions. Results are shown as Pre-GES vs Post-GES (% of change)



References:
1. Minister of Health. GES 71. Cáncer de ovario epitelial. [cited 2024 Sep 30]. Available at: <https://auge.minsal.cl/problemasdesalud/index/71>.
2. Minister of Health. Department of Health Statistics and Information. [cited 2024 Sep 30]. Available at: <https://deis.minsal.cl/>.
3. National Institute of Statistics. Population Projections. [cited 2024 Sep 30]. Available at: <https://www.inec.cl/estadisticas-sociales/demografia-y-vitales/proyecciones-de-poblacion>

Acknowledgements:
We would like to acknowledge Elif Coskuncay from GSK, London, UK for her inputs in the poster, Igloolab for their support on poster design and OPEN Health Communications for the coordination of the review & approval, which was funded by GSK, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).

Disclosures:
This study was funded by GSK (study ID: 222625). Felipe Moraes and Milva Caputo are employed by GSK and do not hold financial equities in GSK. Jose Romero is an employee of GSK and holds financial equities in GSK.

